TROG 98.03 - Prostate - Margin +ve Post-Prostatectomy

TROG 19.06 DECREASE trial marks recruitment milestone

Read our latest Annual Report highlighting TROG achievements

By w.paterson
15 August, 2021
0 Comments

Randomised Trial to Compare the Rates of Disease-Free Survival in Margine-Positive Patients After Radical Prostatectomy With or Without Adjuvant Post-Operative Radiotherapy

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

24 July, 2025

Five questions about the inaugural World Radiotherapy Awareness Day: 7 September

LATEST NEWS: 24 July 2025 The inaugural World Radiotherapy

15 July, 2025

New paper outlines protocol for important TROG 20.01 CHEST-RT lung cancer trial

TRIAL UPDATE: 15 July 2025 The TROG 20.01 CHEST-RT

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Randomised Trial to Compare the Rates of Disease-Free Survival in Margine-Positive Patients After Radical Prostatectomy With or Without Adjuvant Post-Operative Radiotherapy

TROG 98.04 – Liver Metastases

TROG 98.02/EFC3344 – Head & Neck/Tirapazamine (Phase II)

Related Post

Five questions about the inaugural World Radiotherapy Awareness Day: 7 September

New paper outlines protocol for important TROG 20.01 CHEST-RT lung cancer trial

TROG 98.03 – Prostate – Margin +ve Post-Prostatectomy

Randomised Trial to Compare the Rates of Disease-Free Survival in Margine-Positive Patients After Radical Prostatectomy With or Without Adjuvant Post-Operative Radiotherapy

TROG 98.04 – Liver Metastases

TROG 98.02/EFC3344 – Head & Neck/Tirapazamine (Phase II)

Related Post

Five questions about the inaugural World Radiotherapy Awareness Day: 7 September

New paper outlines protocol for important TROG 20.01 CHEST-RT lung cancer trial